1. U.S. Food & Drug Administration. FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection 2021. https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection. Updated 27 Jan 2021.
2. ViiV Healthcare. ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period 2022. https://viivhealthcare.com/en-us/media-center/news/press-releases/2022/march/viiv-healthcare-announces-label-update-for-its-long-acting-hiv/. Updated 24 Mar 2022.
3. ViiV Healthcare. Product monograph for Cabenuva. Laval, Quebec, Canada: ViiV Healthcare ULC; 2020.
4. Margolis DA, Brinson CC, Smith GHR, de Vente J, Hagins DP, Eron JJ, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15(10):1145–55.
5. Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard P-M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124–35.